Diagnostic Testing for Patients with Spinal Muscular Atrophy

Area of Science:

• Genetics
• Neurology
• Pediatrics

Background:

• Spinal muscular atrophy (SMA) is an autosomal recessive disorder.
• Early diagnosis is critical for effective management.
• Targeted treatments are available that significantly improve outcomes.

Purpose of the Study:

• To highlight the importance of diagnostic genetic testing for SMA.
• To emphasize the role of prenatal and newborn screening.
• To underscore the need for rapid genetic confirmation in symptomatic patients.

Main Methods:

• Carrier testing in at-risk parents.
• Fetal testing for homozygous SMN1 gene deletion.
• Newborn screening for SMA.
• Genetic confirmation in symptomatic individuals.

Main Results:

• Genetic testing identifies the vast majority of individuals at risk before symptom onset.
• Early identification allows for prompt initiation of life-altering therapies.

Conclusions:

• Diagnostic genetic testing, including prenatal and newborn screening, is essential for early SMA detection.
• Prompt genetic confirmation in symptomatic patients is vital for accessing timely and effective treatments.
• Early intervention significantly improves quality of life for individuals with SMA.